Parliament Workbench
Data: Official Report to 17 Nov 2026

Official Report · Committee

Current Petitions

Thyroid and Adrenal Testing and Treatment (PE1463)

Tuesday 1 December 2015 Public Petitions Committee About 10:00–10:15 Petitions 57 contributions · 6 speakers

Speakers

Choose an MSP to read only their contributions

The record

57 contributions
Michael McMahon Lab The Convener · Uddingston and Bellshill
link

Agenda item 2 is consideration of current petitions. The first is PE1463, by Lorraine Cleaver, on effective thyroid and adrenal testing, diagnosis and treatment. We are going to take evidence from the petitioner, but I am delighted to say that we have been joined by Elaine Smith MSP, who has an interest in the petition.

As I have said, we will hear first from Lorraine Cleaver. Lorraine, I will open the meeting up to you for two or three minutes, after which we will move to questions. Over to you.

Lorraine Cleaver
link

Thank you, convener, and thanks to the committee for letting me speak today.

As you will know, it has been almost three years since I lodged the petition with two co-petitioners, who have now left the project. I am a bit concerned that the petition has come to a kind of impasse, because at the last meeting at which it was discussed it was agreed that the Scottish intercollegiate guidelines network would look into doing a piece of work on guidelines for the illness.

As I noted in my submission to the committee last week, I had a meeting with SIGN because I have concerns about guidelines. For many illnesses, guidelines are fraught with problems, because they are not about personalised medicine but about putting people in a box. I think that I was right to have those concerns, because it was in the press a few months back that some of the people working on the guidelines committee have financial conflicts of interest—or, certainly, financial interests.

Anyway, we had quite an intensive meeting, the upshot of which was, I think, that SIGN will do a sweep of all the current evidence. Although there is really good evidence backing my petition, the volume of it would be drowned out by the current older evidence, so we could end up with the same old same old at the end of a five-year project.

It was agreed that we would try to work with the Royal College of General Practitioners in Scotland and produce a kind of best practice document. Essentially, though, that would do what should already have been done. It would not actually achieve anything new, which was what I asked for in the petition; it would simply flag up to GPs that if a patient comes to them with continued problems on thyroxine, they should do this, this, this and this. Those guidelines already exist, but they have never been adhered to or noticed.

Although that piece of work would be really useful for 80 per cent of the population with thyroid problems—after all, they go back to their doctors with odd symptoms, and doctors are not aware of the things that they should be doing next, such as checking their B12 levels, iron, cortisol et cetera—it will do absolutely nothing to address the people who have no ability to use levothyroxine, which is the one and only national health service-prescribed medication for the illness and who, according to the Royal College of Physicians, make up 5 to 10 per cent of the population with thyroid problems. I have to say that we think that that figure is a lot higher; in my experience, it is vastly higher than that.

The piece of work that SIGN will conduct will never touch those people, and they were the entire reason why I came to the Public Petitions Committee. Quite apart from that, the work will not address the fact that the medication that I need to stay alive is not available on the NHS and is not licensed in this country. That is a job for the Medicines and Healthcare Products Regulatory Agency.

I do not know whether the committee will recall this, but Alex Neil came to the committee a year and a half or two years ago to give evidence on the situation. Although he acknowledged that it was the MHRA’s job to look into licensing, he said that maybe that situation would change if we got independence—so, of course, it has not changed. I am concerned that, although we have a Scottish NHS, we have no method for looking into the licensing of new drugs for Scottish patients, and I urge the committee to have one more round-table meeting to look again at the fresh evidence that is coming through and which I have discussed on the 10 to 20 per cent of people who do not recover.

The committee could also look at the licensing situation. The European Parliament has closed down my petition there and says that the issue is up to the Medicines and Healthcare products Regulatory Agency. We are just not moving forward in any way. I know why the issue is not being looked at; it is because I am looking for a natural product, and a product from nature cannot be patented, so there is no great will to put a lot of money into research.

However, as the late Dr Skinner said, there is something rather disingenuous in a situation where we have to prove the effectiveness of something that was used for 80 years and was then cast aside and removed from the British national formulary in favour of a new synthetic that did not have to prove its mettle. We are having to prove a negative, which is a ridiculous position to be in. The issue is costing the NHS billions, and the drugs that we are looking for are cheap. There is no reason why Scotland cannot conduct a trial to compare the old natural thyroid with the relatively new levothyroxine, which is giving all the problems.

To sum up, I urge the committee not to close the petition because, in three years, all that we have ultimately achieved is a piece of work by SIGN that has not begun, that might take two years and which will address only patients whom I was never campaigning on behalf of.

Thank you.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

Thanks very much for bringing us up to speed with how things are.

I will come to Elaine Smith first, because she has had a long-standing interest in the issue. Do you want to add some comments before I open it up to questions from the committee?

Elaine Smith Lab Coatbridge and Chryston
link

As Lorraine Cleaver says, she has been working on the issue for more than three years. The committee has looked at the issue and the Government has conducted a listening exercise, although I do not think that we have had anything back from that yet.

To me, the bottom line is that a lot of patients in Scotland are not getting the right treatment, and some of them do not even know that. There are even patients—I know many of them—who should be on levothyroxine but who are deemed as being borderline and are not getting the medicine. Frankly, the whole situation with thyroid medication is a bit of a mess, and it needs much more work done on it. More research needs to be done to show what is happening.

I would not even be sitting here talking to the committee if I had not been able to push my case with my general practitioner, even though I was very ill at the time, to get to the right consultant who was willing to try me out on triiodothyronine—T3—and basically bring me back to life. I have said that to the committee before. That is the bottom line.

It is a shame that so many other people out there are not getting that opportunity, perhaps because their GP is not referring them or because they are not getting to the right consultant. A wee while back, I put together in a hurry about 50 stories for the committee. If members read them, they will find that they basically back up what I am saying and show the situation that people find themselves in. Also, the issue is predominantly although not exclusively for women, so it is a gender issue as well.

A lot could be done in NHS Scotland. Personally, I would like natural desiccated thyroid to be available so that people do not have to go to America to buy their prescriptions. I think that I might do well on that, but I am not willing to go to America. I prefer to work with my consultant and, at the moment, she will not prescribe that because of the situation that she might find herself in.

Obviously, the committee does not have a lot of time left until the end of the session of Parliament. I certainly support Lorraine Cleaver’s request to the committee for another round-table meeting, if you have time to do that. A call for evidence could produce a lot more than the nearly 50 stories that I gave you—you would get hundreds. My plea is that, if you cannot fit that in, you do not close the petition but instead put it in your legacy paper and request the Public Petitions Committee in the next session to look into the matter and consider how it can be taken forward.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

Thanks very much.

Before I go to committee members, I have one question just to absolutely clarify an issue. Would the best practice document that Lorraine Cleaver mentioned be purely for the 5 to 10 per cent who have been identified as the patients for whom the current treatment does not work?

Lorraine Cleaver
link

No. In essence, it would be for the everyday situation that every GP finds of a patient on levothyroxine coming back and saying, “I don’t feel this is working. I don’t feel great, and I’ve still got all these symptoms.”

Where does that figure of 5 to 10 per cent come from? It is quoted in the Royal College of Physicians documents, but other people report a level of 16 per cent. Thyroid UK’s survey for the Scottish Government says that it is higher, and it is for everybody with continued symptoms who goes back to their GP.

Within that figure for people with symptoms is a percentage of people who just cannot tolerate the one NHS drug, yet there is no other provision for them. It is acknowledged that there is a percentage who cannot convert it in their body, but there is absolutely no provision for what to do with them, so they are all getting stuck on anti-depressants.

The document would be useful. GPs try very hard with us heart-sink patients, but ultimately they do not have a document to refer to. It will still not be far reaching enough in any case, because it will not offer them the medication that many of us use—T3 or natural thyroid, which brought me back from the dead.

I hope that you do not mind, but I would like to say something that I forgot to say earlier. I know that you were notified by a coroner about a thyroid suicide last year. It was not put on the website, but I am sure that it has been lodged among the documents. I have probably received about 40 similar letters from families of people who have committed suicide, because of the appalling way in which this illness is treated. To pick up on Elaine Smith’s suggestion, I would say that, if you were to put out a call for evidence, we would have a shocking amount of it to back this claim.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

Just to clarify, I believe that that related to a specific set of circumstances involving an individual. Although committee members might find it useful to have that evidence circulated, just for fullness of information, it could never be put on our website.

Lorraine Cleaver
link

No. I am okay if it is not put on the website.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

I hope that that helps to clarify the situation.

Lorraine Cleaver
link

Yes.

Hanzala Malik Lab Glasgow
link

Good morning. Did you say that a listening document is being put together by the Scottish Government?

Lorraine Cleaver
link

I am sorry—I did not hear what you said.

Lorraine Cleaver
link

The listening exercise?

Lorraine Cleaver
link

The Scottish Government. That was last March or April. It is probably running late with coming back with the results. It asked a charity, Thyroid UK, to conduct a survey of patients and get their views on how they have been treated. The results of that survey have come in and are now back with the Scottish Government. I do not know what the next move is. The results were quite astonishing with regard to the length of time that people are waiting for a diagnosis and how ill they remain when they are on levothyroxine.

Hanzala Malik Lab Glasgow
link

I am happy to continue the petition. It is important to get all the information that we need. If we do not have time ourselves, we could pass it on for another committee to look at.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

We will have a discussion about what to do with the petition at the end of our questioning.

Jim Eadie SNP Edinburgh Southern
link

I seek some clarification, so that I know I have understood the issues correctly. There is medication available called T3, which 5 to 10 per cent of patients do not respond to, although they might benefit from the alternative.

Lorraine Cleaver
link

Five to 10 per cent—allegedly—do not respond to the standard drug levothyroxine, and they request either T3 or natural thyroid.

Jim Eadie SNP Edinburgh Southern
link

Okay. I am just trying to understand the issues with regard to access to treatment.

Lorraine Cleaver
link

It is a very valid question.

Jim Eadie SNP Edinburgh Southern
link

If the manufacturer and the Scottish Government are saying that there are no supply issues, what are the barriers to treatment?

Lorraine Cleaver
link

I do not know where they have got that information from. We have had three supply issues in the past three years, which have been noted by the MHRA and circulated.

Jim Eadie SNP Edinburgh Southern
link

If I have understood it correctly, the information that committee members have received states that, in relation to T3, the Scottish Government was

“not aware of any supply issues having arisen in 2015 ... the manufacturer, AMCo, has advised DH that they are working on an improvement to the manufacturing process ... and are committed to ensuring good supply of this product in the future”.

That suggests that issues are still to be overcome. Can you clarify that for us?

Lorraine Cleaver
link

Yes. That is the only manufacturer of the drug in the UK, which is why it can hold the NHS to ransom and charge more than £100 for 28 tablets. That issue was brought up at a previous meeting here, but nothing has changed. The NHS is paying over the odds for that medication, which is available for €2 in Europe.

Cost is therefore an issue, because GPs do not want to prescribe the drug for cost reasons. In fact, GPs are not actually supposed to prescribe it; they are supposed to refer patients to a consultant endocrinologist. Of course, because of cost cutting, they do not want to do that. They will make the opening gambit to an endocrinologist by email and will be told immediately that the thyroid levels are fine and that it must be something else. As a result, patients are not forwarded to the endocrinologist, and they never really get the T3 that they need. If they get it, they never get enough. There are many problems in all of these areas.

10:15

Jim Eadie SNP Edinburgh Southern
link

For the sake of completeness, can you tell us whether you have had any discussions with the manufacturer or the MHRA about overcoming those issues?

Lorraine Cleaver
link

Yes. I have repeatedly contacted the MHRA and Amdipharm Mercury—I think that that company has had three different names in three years—and I have been consistently told that, because one company makes the drug, it has to recalibrate all its machinery when it does a manufacture run. It forecasts what it will need and if that does not meet the need, it will be another several months before it is ready to recalibrate and make another batch. That is a danger of having one manufacturer in the country of one medication.

The medication is used not just for thyroid patients but for cardiac patients and heart failure. It is quite serious medication.

Elaine Smith Lab Coatbridge and Chryston
link

On the back of Jim Eadie’s questions, I want to ask Lorraine Cleaver to go through the difference between T3 and T4, the conversion issues and the problems with the laboratory testing of the results. Perhaps she can also tell us why other countries have different ranges for their testing results, which might result in different prescriptions in this country.

Lorraine Cleaver
link

Sitting here speaking to members, I feel that they are looking for the gist of the problem. However, the fact is that there are problems with obtaining medication, referral to a specialist and passing the hypothyroid test to be diagnosed, because in this country we have set a reference range of 10. Unless a person gets to the magic figure of 10, they will not be treated; in America, however, the figure is sometimes three, four or 2.5. Different cities have different reference ranges. There is no parity across the board for people being lucky enough to get diagnosed. While people wait for that diagnosis, they can be diagnosed as depressed or as having fibromyalgia, or there could be some other inaccurate result.

I am sorry, but what was the other question that you asked?

Elaine Smith Lab Coatbridge and Chryston
link

I asked you to explain the difference between T3 and T4. Five to 10 per cent do better on T3 or desiccated thyroid.

Lorraine Cleaver
link

The standard medication level of thyroxine that everyone is offered is T4, which is synthetic and is not an active hormone. A person’s body—their liver, gut and peripheral tissue—must convert it into T3 to be active, but there are deiodinase genetic defects and many other reasons why people cannot do that. They might have pituitary, cortisol or iron deficiency issues. There are many reasons that are just never checked when a person repeatedly goes back to a doctor and says that they do not feel well. Although the thyroxine never converts, it will make a blood test look hunky dory and make everything look fine. It will lower a person’s thyroid-stimulating hormone and make everything look fine to the untrained eye. As a result, people are never diagnosed and get neither sufficient treatment nor the correct medication that they need.

When a person has complete thyroid failure, their thyroid is no longer able to produce five things: T1, T2, T3, T4 and calcitonin. The NHS gives people one thing, not five; they are given a synthetic hormone that not everybody can convert, which is total medical negligence. We know for a fact what the thyroid produced when it functioned, and people are given one out of five things and told that that is sufficient.

When my thyroid gland was removed, I was told, “We’ll replace everything that it used to make.” However, they did not. There was a reason why I became obese, bald and suicidal, and there is a reason why people take their lives. We are not talking about depression. This is not in their head, and it is not fibromyalgia; it is simply a lack of thyroid hormone.

John Wilson Ind Central Scotland
link

Welcome again, Lorraine. The committee has considered the petition for a couple of years now, and we thought that we had resolved some of the issues, but it is clear from what we are hearing that we have not resolved the issue of a regular supply of T3. You have indicated that there is only one manufacturer of T3 in the UK. Can you tell me how many manufacturers of T3 there are in Europe?

Lorraine Cleaver
link

Not off the top of my head, John, but there are certainly more than five in mainland Europe. I also happen to know that patients are now booking holidays to Turkey or elsewhere just to come across some T3 medication if it is in short supply here or if they have just been refused it for cost reasons.

John Wilson Ind Central Scotland
link

That is an issue. The drug T3 is available in Europe and manufactured in Europe to European standards, but we seem to have a situation where the MHRA says that we can have only one manufacturer in the UK supplying that drug and that it is not prepared to procure the drug elsewhere.

Lorraine Cleaver
link

Yes, although when there was quite a lengthy shortage last year, the MHRA was prepared to go to Europe, because it had to supply the drug to patients. The loophole was opened when it had to be. However, it is definitely not best practice for the NHS to be overpaying one manufacturer in the UK.

That situation does not address my need for natural thyroid, though, which was ultimately the reason why I wanted to petition the Parliament all those years ago. I do not want to be worried sick for the next 20 or 30 years of my life about being able to import the only medication that I can take. I have tried the NHS T3—levothyroxine—but my endocrinologist has acknowledged that I am just not able to tolerate it at all. When he asked my GP whether he would consider prescribing natural thyroid because lots of his patients were recovering and because he felt that, with its previous fantastic record, it was high time that Scotland conducted some trials on it, I think that my GP’s words were, “It’s more than my job’s worth to prescribe it.”

John Wilson Ind Central Scotland
link

That is what my next question is about. Who manufactures natural desiccated thyroid? Is it manufactured in the UK and Europe, or is it manufactured only in the United States?

Lorraine Cleaver
link

It seems that it is manufactured only in the States, although people are sourcing some that is made in Thailand. I source mine in the States, and it is well controlled under the “United States Pharmacopoeia”. It is safe, but it is still not safe for me to buy drugs online. I do not care what anyone says—this is a ridiculous situation for a 21st century NHS Scotland.

John Wilson Ind Central Scotland
link

And there is no manufacturer of natural desiccated thyroid in the UK.

Lorraine Cleaver
link

Not that I am aware of, no.

John Wilson Ind Central Scotland
link

Clearly, convener, this is an issue of patient care and treatment. I thought that we had resolved it when the previous health secretary came along to the committee and gave us assurances in relation to guidelines by SIGN, the MHRA and others. I will make a suggestion at the end of our questioning about how we take the issue forward.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

To be honest with you, John, I think that we have reached that point. There are no other questions. Hanzala Malik has already—

Jim Eadie SNP Edinburgh Southern
link

Convener, can I ask some final questions?

Jim Eadie SNP Edinburgh Southern
link

Ms Cleaver, you touched just now on the issue of safety. I will read from a letter that the committee received from an official in the Scottish Government, which states:

“In relation to prescribing of desiccated thyroid hormone treatment, it is felt that there is insufficient evidence of benefit and lack of risk, at present, to support the prescribing of thyroid extract and that there are alternatives which have a licence and safety data.”

What you seem to be suggesting with regard to the availability of desiccated thyroid hormone treatment in the United States is that there is probably quite a lot of data available to establish whether there is a risk to patient safety.

Lorraine Cleaver
link

I know what you are saying, but I have just found out—

Jim Eadie SNP Edinburgh Southern
link

I am just wondering why a Scottish Government official would say that there was a lack of safety data. North America is the biggest market for licensed medicines, so I would have thought that over time quite a lot of data would have built up on whether the medication works, its safety profile and so on.

Lorraine Cleaver
link

There is plenty of data. There is over 100 years of data that the medication is safe and effective. Whether it is peer-reviewed, medically collated data, I do not know. I actually do not believe that it is even licensed in the States, although it is still manufactured and commonly used there. There used to be a belief that it was a grandfather drug and that because it had existed for so long, it had been granted safe status and its continued use was no problem. I am not sure that it is even licensed in the States, but it is regularly prescribed. The Food and Drug Administration has a safety profile on it, and it has fewer safety recalls than levothyroxine or liothyronine.

I see what the Scottish Government is saying, which is that we lack a body of evidence to back it up. However, when levothyroxine was introduced in the 1960s and 1970s, it was not trialled on females or on a large number of patients; it was simply introduced. In fact, I have made quite a few comments about that over the past three years.

I have continually asked the MHRA, the National Institute for Health and Care Excellence, the European Medicines Agency and whoever else I could think of, “Can I see this safety data for levothyroxine?” It does not exist. The drug was introduced against the only medication, which was natural thyroid, and now we are being asked to prove that the previous 70 years was a safe period. I do not know how we can prove a negative. Nobody is prepared to do the studies now because, as I have said, there is no money in a natural product—but it is a heck of a saving for the NHS.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

We need to decide what we are going to do with the petition. I take it from what colleagues have said that there is no desire to close it. Indeed, the evidence that we have heard this morning has raised more questions that we need to pursue. Hanzala Malik mentioned an area that we need to go back to the Scottish Government and ask about, and I think that John Wilson has a suggestion.

John Wilson Ind Central Scotland
link

Yes. I suggest that we invite the new Cabinet Secretary for Health, Wellbeing and Sport along to give evidence, particularly in light of the listening exercise report that is supposed to have been produced. We should ask the cabinet secretary to give us feedback on that exercise, answer some of the questions that have been raised today, particularly on the continuing problem with the supply of T3 in the UK, and comment on the natural alternatives that are available.

Lorraine Cleaver mentioned figures that show that up to 16 per cent of patients could benefit, but the reality for many patients out there in society, particularly women, is that if they are not an Elaine Smith—a determined individual who goes and argues with her GP to get referred to the right consultant—they will continue to struggle to get the best treatment. People need treatment that gives them the quality of life that we would all expect.

It is two years since we had the previous cabinet secretary here to answer questions. It would be useful to ask the current cabinet secretary to come along before we move on to consider the possibility of holding our own inquiry. Of course, that might be time barred because of the upcoming elections.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

That is a good suggestion. We should certainly invite the cabinet secretary to the committee to find out whether she takes the same position as her predecessor in relation to the comment that was made earlier about where we could be in the future. We are in a different place from where the previous cabinet secretary wanted us to be, but that does not mean that things cannot be taken forward. I do not always buy into the idea that we would have arrived at the land of milk and honey next year, but we will be able to test that theory if we get the cabinet secretary in front of us to answer our questions and say whether she agrees with the previous incumbent of her post on that matter.

Jim Eadie SNP Edinburgh Southern
link

I thought that Lanarkshire was the land of milk and honey. Laughter.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

It is, Jim. We take that for granted in our part of the world.

Elaine Smith Lab Coatbridge and Chryston
link

May I add one thing? Some of the committee members have changed since the stories that were put together were submitted to the committee. Could they be recirculated to the committee? They give an overview of what people are going through and suffering. Maybe they could even be submitted to the cabinet secretary before she comes to give evidence. They were put together in a hurry, but they give a good indication of what is happening to people across the country.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

Yes. I think that the stories are already available to committee members, but we will certainly take up that suggestion for those who might find that useful.

We will take the petition forward on that basis. I thank Lorraine Cleaver for coming in again this morning.

Lorraine Cleaver
link

Thank you.

Michael McMahon Lab The Convener · Uddingston and Bellshill
link

I suspend the meeting for a couple of minutes.

10:29 Meeting suspended.

10:30 On resuming—

  1. 10:00 Decision on Taking Business in Private Procedure · 1
  2. 10:00 Current Petitions Petitions · 57
  3. 10:15 Current Petitions Petitions · 13
  4. 10:15 Current Petitions Petitions · 17
  5. 10:45 Current Petitions Petitions · 3
  6. 10:45 Current Petitions Petitions · 3
  7. 10:45 Current Petitions Petitions · 1
  8. 10:45 Current Petitions Petitions · 3
  9. 10:45 Current Petitions Petitions · 7
  10. 10:45 Current Petitions Petitions · 3
  11. 10:45 Current Petitions Petitions · 2

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.